

PUBBLICAZIONI INDICIZZATE

DECENNIO 1980-1990

- Polleri A, Savoldi F, Muratorio A, Masturzo P, Murialdo G, Martignoni E, Nappi G, Iudice A, Murri L. Circadian rhythmicity of prolactin secretion in Huntington's chorea. *Life Sci* 1980; 26: 1609-17
- Sandrini G, Alfonsi E, Martignoni E, Horowski R, Nappi G. Effects of lisuride on blink reflex habituation in Parkinson's disease. *Eur Neurol* 1985;24:374-9
- Nappi G, Petraglia F, Martignoni E, Facchinetti F, Bono G, Genazzani A R. Endorphin cerebrospinal fluid decrease in untreated parkinsonian patients. *Neurology* 1985; 35: 1371-4
- Martignoni E, Micieli G, Cavallini A, Pacchetti C, Magri M, Nappi G. Autonomic disorders in idiopathic parkinsonism. *J Neural Transm* 1986; (suppl 22): 149-61

DECENNIO 1990-2000

- Pacchetti C, Martignoni E, Sibilla L, Bruggi P, Turla M, Nappi G. Effectiveness of madopar HBS plus madopar standard in patients with fluctuating Parkinson's Disease: two years of follow-up. *Eur Neurol* 1990; 30: 319-23
- Geminiani G, Cesana BM, Tamma F, Contri P, Pacchetti C, Carella F, Piolti R, Martignoni E, Giovannini P, Girotti F, Caraceni T. Interobserver Reliability Between Neurologists in Training of Parkinson's Disease Rating Scales. *Mov Disord* 1991; 6: 330-5
- Martignoni E, Pacchetti C, Sibilla L, Bruggi P, Pedevilla M, Nappi G. Dihydroergocryptine in the Treatment of Parkinson's Disease: A Six Months' Double-Blind Clinical Trial. *Clin Neuropharmacol* 1991, 14, 78-83
- Nappi G, Martignoni E, Horowski R, Pacchetti C, Rainer E, Runge I. Lisuride plus Selegiline in the treatment of early Parkinson's disease. *Acta Neurol Scand* 1991; 83: 407-10
- Martignoni E, Blandini F, Petraglia F, Pacchetti C, Bono G, Nappi G. Cerebrospinal fluid norepinephrine, 3-methoxy- 4-hydroxyphenylglycol and neuropeptide Y levels in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. *J Neural Transm* 1992; 4: 191-205
- The Italian Parkinson Study Group (in which Martignoni E) A Multicenter Italian randomised study on early treatment of Parkinson disease: comparison of l-dopa, l-deprenyl and dopaminoagonist. Study design and short term results. *Ital J Neurol Sci* 1992; 13: 735-9
- Pacchetti C, Martignoni E, Bruggi P, Godi L, Aufdembrinke B, Miltenburger C, Voet B, Nappi G. Terguride in fluctuating Parkinsonian patients: a double-blind study versus placebo. *Mov Disord* 1993; 8: 463-5
- Pezzoli G, Martignoni E, Pacchetti C, Angeleri VA, Lamberti P, Muratorio A, Bonuccelli U, De Mari M, Foschi N, Cossutta E, Nicoletti F, Giammona F, Canesi M, Scarlato G, Caraceni T, Moscarelli E. Pergolide compared with bromocriptine in Parkinson's disease: a multicenter, crossover, controlled study. *Mov Disord* 1994; 9: 431-6
- Martignoni E, Pacchetti C, Aufdembrinke B, Godi L, Albani G, Mancini F, Nappi G. Terguride in stable parkinson's disease. *Funct Neurol* 1995; 10 : 143-6
- Martignoni E, Pacchetti C, Godi L, Micieli G, Nappi G. Autonomic disorders in Parkinson's disease. *J Neural Transm* 1995; 45: 9-11
- Pacchetti C, Albani G, Martignoni E, Godi L, Alfonsi E, Nappi G. "Off" painful dystonia in Parkinson's disease treated with botulinum toxin. *Mov Disord* 1995; 10: 333-6
- Martignoni E, Horowski R, Liuzzi A, Costa A, Dallabonzana D, Cozzi R, Attanasio R, Rainer E, Nappi G. Effects of terguride on anterior pituitary function in parkinsonian patients treated with L-dopa: a double-blind study vs placebo. *Clin Neuropharmacol* 1996; 19: 72-80
- Martignoni E, Godi L, Pacchetti C, Berardesca E, Vignoli GP, Albani G, Mancini F, Nappi G. Is seborrhea a sign of autonomic impairment in Parkinson's disease? *J Neural Transm* 1997; 104: 1295-304

- Brooks DJ, Abbott RJ, Lees AJ, Martignoni E, Philcox DV, Rascol O, Roos RAC, Sagar HJ. A placebo-controlled evaluation of ropinirole, a novel D2 agonist, as sole dopaminergic therapy in Parkinson's disease. *Clin Neuropharmacol* 1998; 2: 101-7
- Pacchetti C, Aglieri R, Mancini F, Martignoni E, Nappi G. Active music therapy and Parkinson's disease: methods. *Funct Neurol* 1998; 13 (1): 57-67
- Dajas-Bailador FA, Martinez-Borge A, Costa G, Abin AJ, Martignoni E, Nappi G, Dajas F. Hydroxyl radical production in the substantia nigra after 6-hydroxydopamine and hypoxia-reoxygenation. *Brain Res* 1998; 813: 18-25
- Blandini F, Greenamyre JT. Protective and symptomatic strategies for therapy of Parkinson's disease. *Drugs Today* 1999; 35 (6): 473-83
- Martignoni E, Blandini F, Godi L, Desideri S, Pacchetti C, Mancini F, Nappi G. Peripheral markers of oxidative stress in Parkinson's disease. The role of L-Dopa. *Free Rad Biol Med* 1999; 27 (3/4): 428-37
- Blandini F, Martignoni E, Ricotti R, Di Jeso F, Nappi G. Determination of hydroxyl radical formation in human platelets using high-performance liquid chromatography with electrochemical detection. *J Chromatography B* 1999; 732: 213-20
- Blandini F, Conti G, Martignoni E, Colangelo V, Nappi G, Di Grezia R, Orzi F. Modifications of local cerebral metabolic rates for glucose and motor behavior in rats with unilateral lesion of the subthalamic nucleus. *J Cerebr Blood F Met* 1999; 19: 149-54
- Blandini F, Conti G, Nappi G, Zocchi A, Orzi F. Effects of unilateral stimulation of selective striatal dopamine receptors on cerebral metabolism in the rat. *Ital J Neurol Sci* 1999; 20 (4): 6
- Martignoni E, Leoni O, Cosentino M, Corengia E, Fundarò C, Oria C, Michielotto D, Pacchetti C, Mancini F, Lecchini S, Frigo GM, Nappi G. Drug use for neuropsychic disorders in patients with Parkinson's disease. *Ital J Neurol Sci* 1999; 20 (4): OP7
- Conti G, Blandini F, Zocchi A, Orzi F. Effects of stimulation of selective striatal dopamine receptors on local cerebral glucose utilization in the rat. 4th Congress of the European Federation of Neurological Societies. Lisbon, 7-11/09/99. *Eur J Neurol* 1999; 6 (suppl 3): 131

ANNI 2000-2001

- Pacchetti C, Mancini F, Bulgheroni, Zangaglia R, Cristina S, Sandrini G, Nappi G. Botulinum toxin treatment for functional disability induced by essential tremor. *Neurol Sci* 2000;21:349-53
- Blandini F, Nappi G, Tassorelli C, Martignoni E. Functional changes of the basal ganglia circuitry in Parkinson's disease. *Progress in Neurobiology* 2000;62:63-88
- Orzi F, Fornai F, Blandini F. Mapping neuronal activity of the basal ganglia in experimental models of Parkinson's disease: contributions of the (¹⁴C) 2-deoxyglucose method. *Funct Neurol* 2000; 4 (15): 269-76
- Pacchetti C, Mancini F, Aglieri R, Fundarò C, Martignoni E, Nappi G. Active Music therapy in Parkinson's disease: an integrative method for motor and emotional rehabilitation. *Psychosom Med* 2000; 62: 386-93
- LIMPE Lega italiana per la lotta contro la malattia di Parkinson e le sindromi extrapiramidali e le demenze (fra cui Martignoni E). Linee guida per il trattamento della malattia di Parkinson 2000. *Neurol Sci* 2000; 21 S763-813
- Pacchetti C, Cristina S, Mancini F, Fundarò C, Corengia E, Martignoni E, Nappi G. Sintomi non motori nella malattia di Parkinson: procedure per la diagnosi, la terapia e riabilitazione. *Nuova Rivista di Neurologia* 2000;10:87-93
- Martignoni E, Godi L, Corengia E, Zangaglia R, Pacchetti C, Cristina S, Nappi G. Parkinson's disease and acute comorbidity. *Mov Dis* 2000, 15 (Suppl3):188
- Corengia E, Godi L, Citterio A, Zangaglia R, Pacchetti C, Cristina S, Martignoni E, Nappi G. Parkinson's disease and acute comorbidity. *Funct Neurol* 2000; 15:119
- Mancini F, Pacchetti C, Cristina S, Fundarò C, Sandrini G, Nappi G. Botulinum toxin treatment for functional disability induced by essential tremor. *Funct Neurol* 2000; 15: 123
- Pacchetti C, Fundarò C, Cristina S, Corengia E, Mancini F, Gobbo C, Fazio F, Martignoni E,

Nappi G. Psychogenic parkinsonism a case report. *Funct Neurol* 2000; 15:124

- Pacchetti C, Mancini F, Aglieri R, Fundarò C, Martignoni E, Corengia E, Cristina S, Nappi G. Active music therapy in parkinson's disease: an integrative method for motor and emotional rehabilitation. *Funct Neurol* 2000; 15:125
- Orzi F, Conti G, Fornai F, Tassorelli C, Blandini F. Effects of intrastriatal injection of dopamine agonists on local cerebral glucose utilization and fos expression in freely-moving rats. *Eur J Neurosciences* 2000; 12 (suppl. 11): 136
- Blandini F, Conti G, Tassorelli C, Fornai F, Orzi F. Effects of intrastriatal injection of selective dopamine agonists on cerebral metabolism and fos expression in freely-moving rats. *Mov Dis* 2000; 15 (suppl. 3): 18
- Blandini F, Nappi G, Fancellu R, Greenamyre JT. Blockade of NMDA-mediated transmission at the subthalamic level protects nigral dopaminergic neurons and reverts basal ganglia functional changes in a rodent model of Parkinson's disease. *Mov Dis* 2000; 15 (suppl. 3): 18
- Blandini F, Nappi G, Fancellu R, Greenamyre JT. Chronic subthalamic infusion of glutamate antagonists in a rodent model of Parkinson's disease. *Society for Neuroscience* 2000: 1226
- Blandini F, Fancellu R, Martignoni E, Mangiagalli A, Pacchetti C, Corengia E, Fundarò C, Nappi G. Effects of short- and long-term treatment with tolcapone on plasma and platelet levels of l-dopa, 3-O-methyldopa and dopamine in parkinsonian patients. *Funct Neurol* 2000; 15: 119
- Blandini F. Functional changes of basal ganglia circuitry in animal models of Parkinson's disease. *Funct Neurol* 2000; 15: 106

2001

- Albani G, Bulgheroni MV, Mancini F, Mauro A, Fundarò C, Pacchetti C, Sandrini G, Nappi G. The position of the head in space: a kinematic analysis in patients with cervical dystonia treated with botulinum toxin. *Funct Neurol*. 2001 Apr-Jun;16(2):135-41
- Martignoni E, Blandini F, Pacchetti C, Nappi G. COMT inhibition and safety. *Funct Neurol*. 2001;16(4 Suppl):135-40

2002

- Martignoni E, Nappi RE, Citterio A, Calandrella D, Corengia E, Fignon A, Zangaglia R, Riboldazzi G, Pacchetti C, Nappi G. Parkinson's disease and reproductive life events. *Neurol Sci*. 2002 Sep;23 Suppl 2:S85-6.
- Manni R, Pacchetti C, Terzaghi M, Sartori I, Mancini F, Nappi G. Hallucinations and sleep-wake cycle in PD: a 24-hour continuous polysomnographic study. *Neurology*. 2002 Dec 24;59(12):1979-81
- Pacchetti C, Cristina S, Nappi G. Reversible chorea and focal dystonia in vitamin B12 deficiency. *N Engl J Med*. 2002 Jul 25;347(4):295
- Merlo IM, Occhini A, Pacchetti C, Alfonsi E. Not paralysis, but dystonia causes stridor in multiple system atrophy. *Neurology*. 2002 Feb 26;58(4):649-52.

2003

- Blandini F, Nappi G, Fancellu R, Mangiagalli A, Samuele A, Riboldazzi G, Calandrella D, Pacchetti C, Bono G, Martignoni E. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. *J Neural Transm*. 2003 Aug;110(8):911-22.
- Mancini F, Zangaglia R, Cristina S, Sommaruga MG, Martignoni E, Nappi G, Pacchetti C. Double-blind, placebo-controlled study to evaluate the efficacy and safety of botulinum toxin type A in the treatment of drooling in parkinsonism. *Mov Disord*. 2003 Jun;18(6):685-8.
- Cristina S, Zangaglia R, Mancini F, Martignoni E, Nappi G, Pacchetti C. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. *Clin Neuropharmacol*. 2003 May-Jun;26(3):

146-50.

- Pacchetti C, Martignoni E, Terzaghi M, Zangaglia R, Mancini F, Nappi G, Manni R. Sleep attacks in Parkinson's disease: a clinical and polysomnographic study. *Neurol Sci.* 2003 Oct;24(3):195-6.
- Fancellu R, Armentero MT, Nappi G, Blandini F. Neuroprotective effects mediated by dopamine receptor agonists against malonate-induced lesion in the rat striatum. *Neurol Sci.* 2003 Oct;24(3):180-1.
- Blandini F, Mangiagalli A, Martignoni E, Samuele A, Fancellu R, Tassorelli C, Cosentino M, Marino F, Rasini E, Calandrella D, Riboldazzi G, Colombo C, Frigo GM, Nappi G. Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease. *Neurol Sci.* 2003 Oct;24(3):157-8.
- Blandini F, Greenamyre JT. Protective and symptomatic strategies for therapy of Parkinson's disease. *Drugs Today (Barc).* 1999 Jun;35(6):473-83.
- Blandini F, Nappi G, Fancellu R, Mangiagalli A, Samuele A, Riboldazzi G, Calandrella D, Pacchetti C, Bono G, Martignoni E. Modifications of plasma and platelet levels of L-DOPA and its direct metabolites during treatment with tolcapone or entacapone in patients with Parkinson's disease. *J Neural Transm.* 2003 Aug;110(8):911-22.
- Memo M, Blandini F, Nappi G, Spano P. Neuroprotection: promise and pitfalls in anti-inflammatory treatment of Alzheimer's disease. *Funct Neurol.* 2002 Oct-Dec;17(4):175-6.
- Blandini F, Fancellu R, Orzi F, Conti G, Greco R, Tassorelli C, Nappi G. Selective stimulation of striatal dopamine receptors of the D1- or D2-class causes opposite changes of fos expression in the rat cerebral cortex. *Eur J Neurosci.* 2003 Feb;17(4):763-70.
- Spano P, Nappi G, Memo M, Blandini F. Neuronal networks in emotions. *Funct Neurol.* 2002 Jul-Sep;17(3):111-2.
- Blandini F, Fancellu R, Orzi F, Conti G, Greco R, Tassorelli C, Nappi G. Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain.
- Cosentino M, Rasini E, Colombo C, Marino F, Blandini F, Ferrari M, Samuele A, Lecchini S, Nappi G, Frigo G, Martignoni E, Riboldazzi G, Calandrella D, Riva N. Motor complications of Parkinson's disease. *Neurol Sci.* 2003 May;24 Suppl 1:S27-9.
- Blandini F. Dopaminergic modulation of oxidative stress and apoptosis in human peripheral blood lymphocytes: evidence for a D1-like receptor-dependent protective effect. *Free Radic Biol Med.* 2004 May 15;36(10):1233-40.
- Mangiagalli A, Samuele A, Armentero MT, Bazzini E, Nappi G, Blandini F. Effects of homocysteine on apoptosis-related proteins and anti-oxidant systems in isolated human lymphocytes. *Eur J Biochem.* 2004 May;271(9):1671-6.
- Colombo C, Cosentino M, Marino F, Rasini E, Ossola M, Blandini F, Mangiagalli A, Samuele A, Ferrari M, Bombelli R, Lecchini S, Nappi G, Frigo G. Dopaminergic modulation of apoptosis in human peripheral blood mononuclear cells: possible relevance for Parkinson's disease. *Ann N Y Acad Sci.* 2003 Dec;1010:679-82.
- Blandini F, Mangiagalli A, Cosentino M, Marino F, Samuele A, Rasini E, Fancellu R, Martignoni E, Riboldazzi G, Calandrella D, Frigo GM, Nappi G. Peripheral markers of apoptosis in Parkinson's disease: the effect of dopaminergic drugs. *Ann N Y Acad Sci.* 2003 Dec;1010:675-8.
- Blandini F. Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: potential targets for a new therapeutic approach. *Exp Neurol.* 2003 Dec;184(2):556-60.
- Martignoni E, Franchignoni F, Pasetti C, Ferriero G, Picco D. Psychometric properties of the Unified Parkinson's Disease Rating Scale and of the Short Parkinson's Evaluation Scale. *Neurol Sci.* 2003 Oct;24(3):190-1.
- Albani G, Sandrini G, Kunig G, Martin-Soelch C, Mauro A, Pignatti R, Pacchetti C, Dietz V, Leenders KL. Differences in the EMG pattern of leg muscle activation during locomotion in Parkinson's disease. *Funct Neurol.* 2003 Jul-Sep;18(3):165-70.
- Blandini F, Braunewell KH, Manahan-Vaughan D, Orzi F, Sarti P. Neurodegeneration and energy metabolism: from chemistry to clinics. *Cell Death Differ.* 2004 Apr;11(4):479-84.
- Mancini F, Tassorelli C, Martignoni E, Moglia A, Nappi G, Cristina S, Pacchetti C. Long-term

evaluation of the effect of quetiapine on hallucinations, delusions and motor function in advanced Parkinson disease. *Clin Neuropharmacol.* 2004 Jan-Feb;27(1):33-7.

- Martignoni E, Nappi RE, Citterio A, Calandrella D, Zangaglia R, Mancini F, Corengia E, Riboldazzi G, Polatti F, Nappi G. Reproductive life milestones in women with Parkinson's disease. *Funct Neurol.* 2003 Oct-Dec;18(4):211-7.
- Manni R, Terzaghi M, Sartori I, Mancini F, Pacchetti C. Dopamine agonists and sleepiness in PD: review of the literature and personal findings. *Sleep Med.* 2004 Mar;5(2):189-93.
- Pacchetti C, Manni R, Zangaglia R, Glorioso M, Cristina S, Terzaghi M, Ossola M, Tassorelli C, Mancini F, Nappi G. A questionnaire on sleep and mental disorders in Parkinson's disease (QSMDDP): development and application of a new screening tool. *Funct Neurol* 2004; 19 (2): 83-99

CAPITOLI DI LIBRI

- 1, Nappi G, Savoldi F, Martignoni E, Polleri A, 24-hour prolactin secretory pater in Huntington's disease. In: Muller EE, Agnoli A, eds. Neuroendocrine Correlates in Neurology and Psychiatry. Elsevier, Amsterdam, 1979: 151-58
2. Perrari E, Micieli G, Bossolo PA, Martignoni E, Magnani L, Nappi G. Effects of different treatments on the circadian rhythm of plasma prolactin in Parkinson's disease, In: Reinberg A, Smolensky M, Labrecque G, eds. Annual Review of Chronopharmacology 1. Pergarnon Press, 1984 : 25-8
3. Nappi G, Martignoni E. Le malattie degenerative spino-cerebellari e cerebellari, In: Pinelli P, ed. Neurologia. Principi di Diagnostica e Terapia, Casa Editrice Ambrosiana, Milano, 1985: 375-82
5. Nappi G, .Martignoni E, Le. malattie del .sistema extrapiramidale, In: Pinelli P, ed, Neurologia, ' Pnnclpl dl DIagnostIca e TerapIa. Casa Edltnce Ambrosiana, Milano, 1985' 383-401
6. Nappi G, Martignoni E, Micieli G. Ipotalamo e sistema nervoso autonomico. In: Pinelli P, ed. Neurologia. Principi di Diagnostica e Terapia. Casa Editrice Ambrosiana, Milano, 1985: 61- 78
7. Nappi G, Martignoni E, Penoglio L, Sinforiani E. Spettro clinico della malattia di Parkinson e casi borderline. In: Caraceni T, Nappi G, eds. Morbo di Parkinson e Malattie Extrapiramidali. EMI, Pavia, 1985: 157-81
8. Martignoni E, Pacchetti C. Malattia di Parkinson e deterioramento mentale. In: Malattia di Parkinson e declino delle funzioni mentali. Quaderni di Selecta Neurologica. EMI Pavia, 1987: II- 23
9. Martignoni E, Sinforiani E. Malattia di Parkinson e declino delle funzioni mentali. Quaderni di Selecta Neurologica. EMI Pavia, 1987: 1-64
10. Micieli G, Martignoni E, Congedo M, Pacchetti C, Cavallini A, Sibilla L, Nappi G. Malattia di Parkinson e disordini pressori adattativi: correlati biochimici e strumentali. In: Nappi G, Caraceni T, eds. Morbo di Parkinson e malattie extrapiramidali. SelectaNeurologica, EMIPavia, 1987: 187-99
11. Micieli G, Martignoni E, Pacchetti C, Cavallini A, Battaglia A, Nappi G. Cardiopressor effects and safety of nicergoline administred in parkinsonian patients. In: Nappi G, Agnoli A, Fariello R, eds. Neurotoxicology -Basic and clinical research. CIC Edizioni Internazionali Roma, 1987: 201-12
12. Agnoli A, Bruno G, Bellini A, Nappi G, Martignoni E, Meloni C, Boccola V, Proietti G. Neurotoxicity and Parkinson's disease: the role of pesticides. In: Nappi G, Agnoli A, Pariello R, eds. Neurotoxicology -Basic and Clinical Research. CIC Edizioni Internazionali, Roma, 1987: 29
13. Nappi G, Sinforiani E, Facchinetti P, Petraglia F, Bono G, Martignoni E, Genazzani AR. Opioids, aging brain and dementia. In: Nappi G, Hornykiewicz O, Fariello R, Agnoli A, Klavans H, eds. Neurodegenerative Disorders: the Role Played by Endotoxins and Xenobiotics. Raven Press, New York, 1987: 33-42
14. Martignoni E, Nappi G, Micieli G, Sibilla L, Rossi F, Cavallini A, Horowski R. Effects of some dopaminergic ergot-derivatives on cardiovascular adaptative responses in Parkinson's disease. In: Bartko et al, eds. New Trends in Clinical Neuropharmacology. John Libbey, 1988: 321-3
15. Micieli G, Martignoni E, Congedo M, Pacchetti C, Cavallini A, Sibilla L, Nappi G. Parkinson's

- disease and cardiopressor adaptive disturbances: neurochemical and hemodynamic correlates. In: Nappi G, Caraceni T, eds Parkinsonism: Diagnosis and Treatment. Laurel House Publ. Co., 1989: 129-42
16. Pacchetti C, Martignoni E, Sibilla L, Congedo M, Nappi G. Aspetti clinici e fisiopatologici del Parkinson complicato. In: Vecchi GP, Arioli G, Manfredini M, eds. L'assistenza Multidisciplinare in Geriatria: Attualità e Prospettive di Intervento Future. CIC Edizioni Internazionali, Roma, 1989: 13- 20
17. Fioravanti M, Pacchetti C, Sibilla L, Giovannini P, Soliveri P, Turla M, Apollonio MI, Ferrarese C. Indagine sulle relazioni tra caratteristiche cognitive e tipo di terapia dei pazienti parkinsoniani. In: Fioravanti M, Martignoni E et al, eds. Cluster Press, Milano, 1990: 71-93
18. Martignoni E, Pacchetti C, Bruggi P, Sinforiani E, Nappi G. Aspetti clinici e fisiopatogenetici delle disfunzioni cognitive nella malattia di Parkinson. In: Fioravanti M, Martignoni E et al, eds. Disordini Cognitivi nella Malattia di Parkinson. Caratteristiche Cliniche e Terapia. Cluster Press, Milano, 1990: 17-25
19. Cavallini A, Micieli G, Pacchetti C, Bruggi P, Martignoni E, Nappi G. Cardiopressor and neurochemical effects of cabergoline in Parkinson's disease: relevance of postprandial hypotension. In: Yoshizawa M et al, eds. New Trends in Autonomic Nervous System Research. Elsevier Science Publishers BV, Amsterdam, 1991: 226-7
20. Micieli G, Cavallini A, Martignoni E, Pacchetti C, Nappi G. Clinical and functional evaluation of autonomic involvement in parkinsonism and multiple system atrophy. In: Yoshizawa M et al, eds. New Trends in Autonomic Nervous System Research. Elsevier Science Publishers BV, Amsterdam, 1991: 537-8
21. Nappi G, Micieli G, Cavallini A, Martignoni E. Progressive autonomic failure "pure" or associated with the involvement of central nervous system (P AF-MSA). In: Caraceni T, Nappi G, eds. Focus on Parkinson's Disease. Masson, Milano, 1991: 145-53
22. Blandini F, Martignoni E, Bruggi P, Pacchetti C, Petraglia F, Melzi d'Eril GV, Nappi G. Cerebrospinal fluid levels of neuropeptide Y, norepinephrine, and 3-methoxy-4-hydroxy-phenylethylglycol in Parkinson's disease, multiple system atrophy and dementia of the Alzheimer type. In: Felgenhauer K, Holzgraefe M, Prange HW, eds. CNS barriers and modern CSF diagnostics. VCH, Weinheim (Germany), 1993: 376-80
23. Nappi G, Martignoni E. Le malattie del sistema extrapiramidale. In: Pinelli P, Poloni M, eds. Neurologia, Principi di Diagnostica e Terapia. Ambrosiana, Milano, 1993: 387-406
24. Nappi G, Martignoni E, Micieli G. Ipotalamo e sistema nervoso autonomico. In: Pinelli P, Poloni M, eds. Neurologia. Principi di Diagnostica e Terapia. Ambrosiana, Milano, 1993: 63-79
25. Nappi G, Martignoni E, Sandrini G. Malattie degenerative spinocerebellari. In: Pinelli P, Poloni M, eds. Neurologia, Principi di Diagnostica e Terapia. Ambrosiana, Milano, 1993: 379-86
26. Pacchetti C, Godi L, Albani G, Martignoni E. Fisiopatologia del Parkinson complicato. In: Moglia A, Ceroni M, Molinari S, eds. Conferenze e Seminari in Neuroscienze 1993 dell'Istituto Neurologico C. Mondino. ASK Edizioni, Varese, 1994: 79-84
27. Martignoni E, Pacchetti C, Albani G, Godi L, Nappi G. The role of pergolide in Parkinson's disease. In: Nappi G, Caraceni T, Martignoni E, Giovannini P. New Advances in Parkinson's Disease and Other Extrapiramidal Disorders. Smith-Gordon, Londra, 1994: 87-93
28. Martignoni E, Pacchetti C, Micieli G, Nappi G. Autonomic disturbances in Parkinson's disease and

Shy-Drager syndrome. In: Korczyn AD, ed. Handbook of Autonomic Nervous System, Marcel Dekker Inc., New York, 1995: 235-52

LIBRI

1. Martignoni E, Sinforiani E. Malattia di Parkinson e declino delle funzioni mentali. Quaderni di Selecta Neurologica. Emi, Pavia, 1987: 1-64
2. Nappi G, Agnoli A, Martignoni E, Castellani A. Updating in Parkinson's disease. Funct Neurol; num.3, CIC Edizioni Internazionali, Roma, 1988: 379-479
3. Gershanik OS, Martignoni E, Melagrano R, Nappi G. Parkinson's disease '89. Proceedings of the Italian-Brasilian-Argentinian Meeting. Func Neurol; suppl4
4. Fioravanti M, Martignoni E, Girotti F, Ferrarese E, Scarzella L. Disordini cognitivi nella Malattia di Parkinson. Cluster Press, Milano, 1990
5. Nappi G, Caraceni T, Martignoni E, Giovannini P. New Advances in Parkinson's Disease and Other Extrapiramidal Disorders. Smith-Gordon, Londra, 1994; 1-147